Your web browser does not support JavaScript, but it does not affect browsing through the rest of the web site. Go to Main Content

Biomedical Technologies

:::
Bio-Printing Technology for Full Thickness Skin Tissue
A 3D Micro Precision Construction Technology has been developed for tissue engineering.
To enhance the technical competitive advantages of Taiwan’s cell therapy industry, ITRI’s team focuses on developing the serum-free mediums, the Mesenchymal Stem Cell Mass Production Technology, and the establishment of a cell bank for clinical use.
Antibody-Drug Conjugates (ADCs)
ITRI has developed a new generation drug delivery technology, Antibodydrug Conjugate (ADC), which can not only differentiate cancer cells from normal cells but also precisely deliver drugs to the cancer cells to kill them without harming healthy ones.
Fabrication Techniques for Biomimetic Magnetic Beads with Multi-Protrusions
The immune system is critical in fighting cancer, and T cells are able to identify and destroy cancer cells.
Development Platform Technology for Botanical and Plant-Derived Drugs
ITRI provides manufacturers with complete services, ranging from the production, management, and control of medicinal materials to relevant certifications and applications in order to compensate for the lack of technologies in the industry. It has also strengthened Taiwan’s R&D capabilities in the pharmaceutical industry to expedite the process of launching domestically developed drug products to the market.
High Yield Breeding Technology for Photosynthetic Microalgae
Microalgae can effectively use light and CO2 to produce biomass. In addition to their applications in the food, feed, cosmetics, and pharmaceuticals industries, microalgae are also recognized as promising feedstocks for the production of biofuels and chemicals. ITRI has developed active substances and biomimetic compounds to promote the growth of microalgae.
Novel Lymphatic Delivery System for Cancer Metastasis
Metastasis occurs mainly via the lymphatic system. To treat late-stage cancer that has spread to lymph nodes, ITRI has developed the Novel Lymphatic Delivery System for Cancer Metastasis.
To develop Taiwan’s own cell therapy core technology in synchrony with global trends, ITRI invests in R&D on allogeneic mesenchymal stem cell (MSC) based therapeutic technologies and products.
Soft Material Additive Manufacturing Technology
ITRI’s Soft Material Additive Manufacturing Technology uses a guided and adjustable temperature nozzle design to solve the problem of blocked nozzles caused by soft materials (such as Thermoplastic Polyurethane, TPU).
GMP Production Platform of Botanical New Drugs for Clinical
ITRI’s GMP–certified pilot plant for botanical drugs and quality analysis laboratory were built to support domestic producers in botanical medicine development.